Clinical Cancer Research Bridging the Lab and the Clinic in Cancer Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pommier, Y.
Right arrow Articles by Kohn, K. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pommier, Y.
Right arrow Articles by Kohn, K. W.
Clinical Cancer Research Vol. 12, 2657-2661, May 1, 2006
© 2006 American Association for Cancer Research

Molecular Pathways

Chk2 Molecular Interaction Map and Rationale for Chk2 Inhibitors

Yves Pommier, John N. Weinstein, Mirit I. Aladjem and Kurt W. Kohn

Authors' Affiliation: Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland

Requests for reprints: Yves Pommier, NIH, Room 5068, Building 37, Bethesda, MD 20892-4255. E-mail: pommier{at}nih.gov.


   Abstract
Top
 Abstract
Chk2 MIM
 Clinical Translational Advances
 References
 
To organize the rapidly accumulating information on bioregulatory networks related to the histone {gamma}-H2AX-ATM-Chk2-p53-Mdm2 pathways in concise and unambiguous diagrams, we used the molecular interaction map notation (http://discover.nci.nih.gov/min). Molecular interaction maps are particularly useful for networks that include protein-protein binding and posttranslational modifications (e.g., phosphorylation). Both are important for nearly all of the proteins involved in DNA double-strand break signaling. Visualizing the regulatory circuits underlying cellular signaling may help identify key regulatory reactions and defects that can serve as targets for anticancer drugs.

DNA double-strand breaks (DSB) are among the most severe genomic lesions. Their repair requires cells to arrest cell cycle progression to avoid further damage during replication or transcription (1–5). Cell cycle arrest may also allow the chromatin to switch from a metabolic (replicative) state to a repair state. DSB can be produced directly by ionizing radiation and certain anticancer drugs that bind to DNA (e.g., bleomycin, neocarcinostatin, topoisomerase II inhibitors, such as etoposide or doxorubicin). DSB can also result from conversion of single-strand breaks by DNA polymerase collisions or "replication fork collapse" at sites of damaged DNA. Replication DSB occur normally in cancer cells, but their frequency is markedly enhanced by topoisomerase I inhibitors such as the camptothecin derivatives (e.g., topotecan and irinotecan; ref. 6) and DNA alkylating agents.

The importance of Chk2, a protein involved in cell cycle arrest due to DSB, is indicated by its conservation in eukaryotes (7–10). However, yeast and vertebrate cells can survive without Chk2, although they are defective in cell cycle checkpoints and apoptosis after irradiation. Chk2 activation by camptothecin treatment has been reported to be defective in several colon carcinoma cell lines from the NCI 60 cell line screen (11). Chk2 inactivation in humans with normal p53 leads to Li-Fraumeni syndrome (12), supporting a genetic connection between Chk2 and p53 and the existence of a Chk2-p53 axis [see the molecular interaction map (MIM) Fig. 1 ]. Families with Chk2 deficiencies have been identified among patients with increased risk of breast cancer (10, 13, 14).


Figure 1
View larger version (47K):
[in this window]
[in a new window]
  		Fig. 1. MIM centered on the ATM-Chk2-p53 axis. A fully annotated version, including references for each molecular species and interactions, can be found in the Supplementary Data, and as an electronic interactive version at the Discover Web site.1 Bottom, symbols and convention keys. Top, MIM describing the interactions between a DSB (input box at the top) and three output boxes ("Repaired DNA," "Cell Cycle Checkpoint," and "Apoptosis"). The six shaded boxes (modules/nodes) numbered with roman numerals are as follows: Figure 1, chromatin; Figure 1, sensor proteins with BRCT domains (shaded in purple); Figure 1, ATM activation node; Figure 1, Chk2 activation node; Figure 1, cell cycle checkpoint; and Figure 1, p53 node. Blue boxes, Chk2 substrates. Arabic numbers, annotations used in the text. These annotations are fully explained individually in Supplementary Data and in the electronic MIM at the Discover Web site1 with complete sets of references directly linked to PubMed.

 
Chk2 functions as a kinase relay for ATM (refs. 9, 15, 16; see MIM), whose gene (ataxia telangiectasia mutant) is mutated in ataxia telangiectasia patients (2). It is generally accepted that DNA damage triggers two main pathways (16). DSB activate the ATM-Chk2 axis, whereas replication lesions activate the ataxia telangiectasia and rad3-related kinase (ATR)–Chk1 axis. However, there is crosstalk between the two pathways and certain lesions activate both. In such cases, the ATM-Chk2 axis is activated first and transiently, whereas the ATR-Chk1 axis is activated secondarily and in a more sustained way (17). The association of Chk1 with replication damage is consistent with the cell cycle–dependent expression of Chk1, which increases during S-phase and peaks in G2. In contrast, Chk2 is expressed throughout the cell cycle, consistent with its broader role in response to DSB produced both during S-phase and independently of replication (18).

Although Chk2 shares no sequence homology with Chk1, crosstalk between the Chk2 and Chk1 pathways is also indicated by the observation that several Chk2 substrates (e.g., Cdc25C and p53, highlighted in blue in Fig. 1) are also Chk1 substrates and are phosphorylated by both kinases on the same amino acid residues (9).


   Chk2 MIM
Top
 Abstract
 Chk2 MIM
Clinical Translational Advances
 References
 
Foreword. To organize the rapidly accumulating information on bioregulatory networks in concise and unambiguous diagrams, we crafted the MIM notation (ref. 19).1 MIMs are particularly useful for networks that include protein-protein binding and posttranslational modifications (e.g., phosphorylation). Both are important for nearly all of the proteins involved in DNA damage signaling by the ATM-Chk2 axis. The MIM allows one to trace pathways and loops in the networks, thereby helping to interpret data and formulate testable hypotheses (Fig. 1).

Molecular species and events in the MIM fall into three categories indicated to the right of the MIM: (a) chromatin, (b) sensors and kinases, and (c) effectors. Symbol definitions are shown below the MIM. Arabic numbers in the map refer to text and literature references listed in the Supplementary Data and at the Discover Web site.1 Maps at the Discover Web site are interactive (electronic). The user can navigate MIM and link to electronic molecular databases. Clicking on a molecular species activates links to Genbank, Entrez Nucleotide, Entrez Genome, PubMed, GeneCards, MatchMiner, CGAP, MedMiner, and Glossary. Clicking on the annotation numbers opens a text window describing the molecular interaction and listing references, with links to PubMed. The symbology and complete reference list can be found in Supplementary Data and at the Discover Web site1 (Chk2 Map). Furthermore, we recently published a detailed MIM for the p53-Mdm2 module (20).

Brief description of the Chk2-ATM-p53 MIM. The input signal "DSB" is shown in a box outlined in red at the top of the map. The outputs, "Cell Cycle Checkpoints" and "Apoptosis" are also shown in red boxes at the bottom. "Repaired DNA," another output, is shown to the left of the DSB. The signaling pathways are labeled with number-letter combinations followed by the map coordinates.

The pink box (Formula , A3) indicates a group of chromatin events at the DSB site. DSB stimulate phosphorylation of histone H2AX on serine 139 by DNA-PK and ATM [1,A3]. Phosphorylated H2AX (known as {gamma}-H2AX) then further stimulates (or amplifies) the DSB-induced stimulation of ATM [1a,A2]. {gamma}-H2AX is also required for binding of sensor proteins to altered chromatin [1b,A2] and for keeping the ends the DSB in close proximity (21). Protein complexes containing BRCT domains are grouped in the purple box at left (Formula ). They include 53BP1, MDC1, Nbs1 (which is part of the trimeric MRN complex [2,B2] with Mre11 and Rad50), and BRCA1 [C2]. Those proteins contribute to the full activation of ATM, at least in part by providing scaffolds that enable ATM to recruit and process its various substrates [2d,B2] (22, 23). Mre11-Rad50 can directly act as a repair nuclease [2e,A2].

Box Formula shows events in ATM activation. ATM normally exists as an inactive dimer [3,B3]. Binding of the ATM dimer to altered chromatin changes its configuration, allowing autophosphorylation (in trans) at serine 1981. The histone acetyl transferase TIP60 is also required for ATM activation [3c,A3]. Phosphorylation dissociates the ATM dimer, fully activating ATM. ATM phosphorylates the BRCT domain sensor proteins [3d-e,B1-C3], perhaps providing positive feedback between ATM and the BRCT-containing proteins. ATM directly phosphorylates many other molecules (only some of which are represented on the map): MdmX [3f,D2], p53 [3g,D3], E2F1 [3h,D5], and Chk2 [3i,C3]. It is striking that four of the nine ATM substrates shown are also Chk2 substrates (discussed below).

The Chk2 activation loop is shown in box Formula . Phosphorylation of Chk2 at threonine 68 by ATM [3i,C3] induces Chk2 dimerization, which is required for Chk2 activity [4,C4]. Once dimerized, Chk2 is further activated by autophosphorylation in trans at residues 383, 387, and 516 [4a,B4]. Thus, Chk2 is active as a dimer, whereas ATM is active as a monomer. Chk2 phosphorylates a range of proteins involved in cell cycle control and apoptosis. The Chk2 substrates besides itself are shown in blue: cdc25A [C1], cdc25C [D1], MdmX [D2], p53 [D3], PML [D4], E2F1 [D5], and phosphatase 2A (PP2A [C4]).

Checkpoint activation causes cell cycle arrest. Under normal conditions, Cdc25 phosphatases (box Formula ) stimulate the activation of cyclin-dependent kinases [5,D1]. Two Cdc25s are Chk2 substrates: Cdc25A and Cdc25C, which are required to promote cell cycle progression through G1-S and G2, respectively. Cdc25A and C are both inactivated following phosphorylation by Chk2 [5a and 5b,D1]. The BRCT domain proteins (box Formula ) also contribute to cell cycle checkpoint control [2e,C2].

The p53 module (Formula ; ref. 20) is a major target of Chk2. Under normal conditions, p53 [D3] levels are kept low because p53 is degraded by Mdm2 [D2]. Binding of p53 to Mdm2 [6,D3] results in p53 polyubiquitination, which then induces p53 degradation [6a,D3]. Binding of MdmX to Mdm2 may further activate Mdm2 [6b,D2]. Binding of Mdm2 to p53 inhibits p53 by two additional mechanisms: transcriptional inhibition of p53 target genes [6c,D3] and export of p53 from the nucleus (not shown). Chk2 activates p53 by at least three mechanisms: two resulting from direct phosphorylation of p53 [4e,D3] and one indirectly by phosphorylation of MdmX [4f,D3]. Phosphorylation of p53 at serine 20 [4e,D3] inhibits its binding to Mdm2 [6d,D3] and therefore increases p53 levels. p53 phosphorylation at serine 20 also enhances p53 transcriptional activity [6e,D3]. Phosphorylation of MdmX [4f,D3] leads to MdmX degradation and thereby reduces p53 inhibition by Mdm2. This convergence of several mechanisms for p53 activation by Chk2 is remarkable. The apparent robustness of the molecular network underscores the importance of p53 activation by Chk2.

Two outcomes of p53 activation are represented in the MIM: cell cycle arrest and apoptosis. Cell cycle arrest [6f,E2] is mediated by the transcriptional activation of genes exemplified by CDKN1 (p21waf1/cip1) and Gadd45 [6g,E3]. In contrast, transcriptional activation of genes such as Bax, Noxa, Puma, and Fas [6h,E4] favors apoptosis. ASPP1 and ASPP2 associate with p53 on the promoters of proapoptotic genes [6i,E4] and switch the transcriptional activity of p53 toward apoptosis. p53 can also stimulate apoptosis by actions at mitochondria (for instance, by targeting Bax and Bak) [6j,D4] (20). Finally, p53 can inactivate itself by transactivating Mdm2 gene expression (negative feedback) [6k,D2]. Thus, a coherent picture of the control of p53 emerges. First, p53 is rapidly stabilized/activated by a convergent set of phosphorylations of both p53 and MdmX by Chk2. Later, p53 activates cell cycle arrest and apoptosis by transcriptional activation. Finally, p53 can turn itself off by transactivating Mdm2.

Two other Chk2 substrates further reinforce the proapoptotic function of Chk2: PML and E2F1. Phosphorylation of PML at serine 117 [4g,D4] enhances PML-dependent apoptosis. Phosphorylation of E2F1 at serine 364 [4h,D5] stabilizes E2F1 and induces apoptosis in both p53-dependent and p53-independent ways. As a transcription factor, E2F1 transactivates p14 (ARF) [7,E4], which activates p53 by inducing its dissociation from Ndm2. E2F1 also transactivates ASPPs [7a,E5] and Chk2 [7c,C3] and activates ATM [7d,B5], which further activates p53 and both p53-dependent and p53-independent apoptosis (see above). Finally, E2F1 can induce apoptosis independently of p53 by transactivating p73 and Apaf1 [7b,E5].

The last Chk2 substrate in the MIM is phosphatase 2A (PP2A [C4]) whose activation by Chk2 [4i,C3] induces its recruitment to {gamma}-H2AX foci [8,C4]. {gamma}-H2AX dephosphorylation [8,A3] is critical for cell recovery following DSB and checkpoint activation. Failure to dephosphorylate {gamma}-H2AX increases cell sensitivity to DNA damage. The phosphatase 2C (PP2C/Wip1) has recently been implicated in turning off Chk2 activation by ATM by dephosphorylating threonine 68 of Chk2 [9,B3]. Because Wip1 is a p53-responsive gene, both PP2A and PP2C probably act as negative feedback loops within the Chk2 molecular network that terminates checkpoint control once repair has taken place. Overall, these linked phosphorylation-dephosphorylation couples suggest intricate control possibilities, the elucidation of which will be an interesting challenge for theory and experiments (24, 25).

Overview of the Chk2-ATM-p53 MIM. The MIM underlines some remarkable features of the ATM-Chk2-p53 axis/network with its several positive and negative feedback loops, convergence of signals to achieve key molecular outputs, and coupled ATM- and Chk2-mediated phosphorylation of p53 and other dual ATM-Chk2 substrates. The positive feedback loops include: (a) ATM activation (module III); (b) Chk2 activation (module IV); (c) the H2AX-ATM activation loop (between modules I and III) with the BRCT-containing proteins (module II) acting as amplifier; and (d) E2F1-induced activation of both ATM and Chk2. These positive feedback loops suggest a regulated (and perhaps temporally sustained and/or synergistic) activation of each step of the pathway.

Convergence of cycle arrest/checkpoint signals cell from both the Cdc25 module and the p53-p21cip1/waf1 network underlines their importance for DSB response. Convergence is also illustrated within the p53 module (VI), where p53 is activated both directly by Chk2 and indirectly by MdmX-Mdm2. Such coherences can contribute to robustness of the system.

The significance of the dual phosphorylation by ATM and Chk2 of most of the substrates (p53, MdmX, E2F1, and Chk2 itself) remains to be understood. Dual phosphorylations may provide fine tuning for conditional activation. Finally, negative feedback loops, such as the Mdm2-p53 interaction and the PP2A-mediated inactivation of {gamma}-H2AX and the Wip1-mediated inactivation of Chk2, suggest that the ATM-Chk2-p53 network may be autoregulated by switching itself off to allow transient cell cycle inhibition coupled with DNA repair.


   Clinical Translational Advances
Top
 Abstract
 Chk2 MIM
 Clinical Translational Advances
References
 
Two main observations justify the development of Chk2 inhibitors. First, a significant fraction of tumors and precancerous lesions overexpress activated Chk2 (26, 27). Hence, such tumors may be "dependent upon" ("addicted to") activated Chk2. Chk2 may be required to respond to DNA lesions resulting from the genomic instability and aberrant replication that characterize a large fraction of tumors, thereby allowing the transformed and malignant cells to survive.

Second, Chk2 is activated in tumor cells by a wide range of commonly used chemotherapeutic agents, including ionizing radiation, topoisomerase inhibitors, and DNA-targeted agents. Because of the dual function of Chk2 (induction of p53-dependent apoptosis and cell cycle checkpoint activation coupled with DNA repair), it is plausible that a Chk2 inhibitor would increase the therapeutic indices of DNA-targeted agents (9). In tumors defective for apoptosis (and p53), the Chk2 inhibitor would act primarily as a checkpoint inhibitor and prevent DNA repair, whereas in normal tissues (with functional p53) the Chk2 inhibitor would primarily block apoptosis and subsequent side effects.


   Acknowledgments
 
We thank the current and past members of the Laboratory of Molecular Pharmacology for their insights and suggestions, more specifically Dr. Andy Jobson and Dr. V. Ashutosh Rao, and Dr. William Bonner, member of the laboratory of Molecular Pharmacology, for his landmark contribution—the discovery of histone {gamma}-H2AX. We also thank David Kane, Margot Sunshine, and Hong Cao (on contract from SRA international, Inc.) for their excellent assistance in the implementation of the electronic interactive MIM on the Discover Website.


   Footnotes
 
Grant support: Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research.

1 http://discover.nci.nih.gov/mim. Back

Note: Supplementary data for this article are available at Clinical Cancer Research Online (http://clincancerres.aacrjournals.org/) and at the Discover Website.1 Back


   References
Top
 Abstract
 Chk2 MIM
 Clinical Translational Advances
 References
 

  1. Zhou BB, Elledge SJ. The DNA damage response: putting checkpoints in perspective. Nature 2000;408:433–9.[CrossRef][Medline]
  2. Shiloh Y, Lehmann AR. Maintaining integrity. Nat Cell Biol 2004;6:923–8.[CrossRef][Medline]
  3. Bakkenist CJ, Kastan MB. Initiating cellular stress responses. Cell 2004;118:9–17.[CrossRef][Medline]
  4. Kurz EU, Lees-Miller SP. DNA damage-induced activation of ATM and ATM-dependent signaling pathways. DNA Repair (Amst) 2004;3:889–900.
  5. Bradbury JM, Jackson SP. The complex matter of DNA double-strand break detection. Biochem Soc Trans 2003;31:40–4.[Medline]
  6. Pommier Y, Redon C, Rao A, et al. Repair of and checkpoint response to topoisomerase I-mediated DNA damage. Mutat Res 2003;532:173–203.[Medline]
  7. Bartek J, Falck J, Lukas J. Chk2 kinase—a busy messenger. Nat Rev Mol Cell Biol 2001;2:877–86.[CrossRef][Medline]
  8. Ahn J, Urist M, Prives C. The Chk2 protein kinase. DNA Repair (Amst) 2004;3:1039–47.
  9. Pommier Y, Sordet O, Rao A, Zhang H, Kohn KW. Targeting Chk2 kinase: molecular interaction maps and therapeutic rationale. Curr Pharm Des 2005;11:2855–72.[CrossRef][Medline]
  10. Craig AL, Hupp TR. The regulation of CHK2 in human cancer. Oncogene 2004;23:8411–8.[CrossRef][Medline]
  11. Takemura H, Rao VA, Furuta T, et al. Mre11 is commonly inactivated in human colon carcinoma cells and is required to stabilize Rad50-1 and to cooperate with ATM to activate Chk2 in response to replication-dependent DNA double-strand breaks. Proc Am Assoc Cancer Res 2006;47:188 (#799).
  12. Bell DW, Varley JM, Szydo TE, et al. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 1999;286:2528–31.[Abstract/Free Full Text]
  13. Cipollini G, Tommasi S, Paradiso A, et al. Genetic alterations in hereditary breast cancer. Ann Oncol 2004;15 Suppl 1:I7–13.
  14. Kwak EL, Kim S, Zhang J, Cardiff RD, Schmidt EV, Haber DA. Mammary tumorigenesis following transgenic expression of a dominant negative CHK2 mutant. Cancer Res 2006;66:1923–8.[Abstract/Free Full Text]
  15. Shiloh Y. ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer 2003;3:155–68.[CrossRef][Medline]
  16. Bartek J, Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 2003;3:421–9.[CrossRef][Medline]
  17. Jazayeri A, Falck J, Lukas C, et al. ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks. Nat Cell Biol 2006;8:37–45.[CrossRef][Medline]
  18. Lukas C, Bartkova J, Latella L, et al. DNA damage-activated kinase Chk2 is independent of proliferation or differentiation yet correlates with tissue biology. Cancer Res 2001;61:4990–3.[Abstract/Free Full Text]
  19. Kohn KW, Riss J, Aprelikova O, Weinstein JN, Pommier Y, Barrett JC. Properties of switch-like bioregulatory networks studied by simulation of the hypoxia response control system. Mol Biol Cell 2004;15:3042–52.[Abstract/Free Full Text]
  20. Kohn KW, Pommier Y. Molecular interaction map of the p53 and Mdm2 logic elements, which control the off-on switch of p53 in response to DNA damage. Biochem Biophys Res Commun 2005;331:816–27.[CrossRef][Medline]
  21. Bassing CH, Alt FW. H2AX may function as an anchor to hold broken chromosomal DNA ends in close proximity. Cell Cycle 2004;3:149–53.[Medline]
  22. Glover JN, Williams RS, Lee MS. Interactions between BRCT repeats and phosphoproteins: tangled up in two. Trends Biochem Sci 2004;29:579–85.[CrossRef][Medline]
  23. Stucki M, Jackson SP. {gamma}H2AX and MDC1: anchoring the DNA-damage-response machinery to broken chromosomes. DNA Repair (Amst) 2006. Epub ahead of print.
  24. Sauro HM, Kholodenko BN. Quantitative analysis of signaling networks. Prog Biophys Mol Biol 2004;86:5–43.[CrossRef][Medline]
  25. Kholodenko BN. Cell-signalling dynamics in time and space. Nat Rev Mol Cell Biol 2006;7:165–76.[CrossRef][Medline]
  26. Gorgoulis VG, Vassiliou LV, Karakaidos P, et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005;434:907–13.[CrossRef][Medline]
  27. Bartkova J, Horejsi Z, Koed K, et al. DNA damage response as a candidate anticancer barrier in early human tumorigenesis. Nature 2005;434:864–70.[CrossRef][Medline]



This article has been cited by other articles:


Home page
 Nucleic Acids ResHome page
M. Tozluoglu, E. Karaca, T. Haliloglu, and R. Nussinov
Cataloging and organizing p73 interactions in cell cycle arrest and apoptosis
Nucleic Acids Res., September 1, 2008; 36(15): 5033 - 5049.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
V. T. Mihaylova, A. M. Green, M. Khurgel, O. J. Semmes, and G. M. Kupfer
Human T-Cell Leukemia Virus I Tax Protein Sensitizes p53-Mutant Cells to DNA Damage
Cancer Res., June 15, 2008; 68(12): 4843 - 4852.
[Abstract] [Full Text] [PDF]

Home page
 Am Soc Clin Oncol Ed BookHome page
Y. Pommier
DNA Repair Modulators as Anticancer Agents
ASCO Educational Book, January 1, 2008; 2008(1): 128 - 133.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
A. G. Jobson, J. H. Cardellina II, D. Scudiero, S. Kondapaka, H. Zhang, H. Kim, R. Shoemaker, and Y. Pommier
Identification of a Bis-guanylhydrazone [4,4'-Diacetyldiphenylurea-bis(guanylhydrazone); NSC 109555] as a Novel Chemotype for Inhibition of Chk2 Kinase
Mol. Pharmacol., October 1, 2007; 72(4): 876 - 884.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
V. A. Rao, C. Conti, J. Guirouilh-Barbat, A. Nakamura, Z.-H. Miao, S. L. Davies, B. Sacca, I. D. Hickson, A. Bensimon, and Y. Pommier
Endogenous {gamma}-H2AX-ATM-Chk2 Checkpoint Activation in Bloom's Syndrome Helicase Deficient Cells Is Related to DNA Replication Arrested Forks
Mol. Cancer Res., July 1, 2007; 5(7): 713 - 724.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
S. Ray, S. Shyam, G. C. Fraizer, and A. Almasan
S-phase checkpoints regulate Apo2 ligand/TRAIL and CPT-11-induced apoptosis of prostate cancer cells
Mol. Cancer Ther., April 1, 2007; 6(4): 1368 - 1378.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
H. Takemura, V. A. Rao, O. Sordet, T. Furuta, Z.-H. Miao, L. Meng, H. Zhang, and Y. Pommier
Defective Mre11-dependent Activation of Chk2 by Ataxia Telangiectasia Mutated in Colorectal Carcinoma Cells in Response to Replication-dependent DNA Double Strand Breaks
J. Biol. Chem., October 13, 2006; 281(41): 30814 - 30823.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pommier, Y.
Right arrow Articles by Kohn, K. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pommier, Y.
Right arrow Articles by Kohn, K. W.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online